Through OmniaBio’s CDMO manufacturing facilities, MEDIPOST provides client companies planning overseas clinical trials in North America with an “all-in-one package” covering development, manufacturing, quality testing, and regulatory support for advanced biopharmaceuticals — including cell therapy manufacturing technology built to global standards — from process development through commercial-scale production.
OmniaBio Overview
Located in Toronto, Canada — a hub for healthcare R&D — OmniaBio is MEDIPOST’s strategic Global CDMO partner, providing CDMO services for cell and gene therapy developers seeking rapid clinical progress toward the North American market.
Centre for Advanced Therapeutic Cell Technologies (CATCT, Toronto, ON):
specialized staff; 10,000 sq. ft. research facility; manufacturing technology and process development
Centre for Cell and Vector Production (CCVP, Toronto, ON):
120 specialized staff; 20,000 sq. ft. facility; 8 cell therapy suites / 2 viral vector suites / QC laboratory
OmniaBio Plant
OmniaBio’s new plant (Hamilton, ON) is a facility built to scale up Global CDMO services for cell and gene therapies, opened in October 2024 and now running at full GMP suite capacity.
500+ specialized staff (phased expansion)
15 suites (100,000 sq. ft.)
MSAT, PD, QC (15,000 sq. ft.)
In-house training facility
· OmniaBio GMP Facility
– Location : Toronto, Canada
– Business : Cell & Gene Therapy, Global CMO/CDMO
· MEDIPOST GMP Center
– Location : Guro, Seoul
– Business : Cell Therapy, Domestic CMO/CDM